MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

The cost of the Cobenfy is set to be in line with most other antipsychotic medications on the market. Adam Lenkowsky, chief commercialization officer for BMS, told the Times that its wholesale ...

BMS set a $1,850 per month wholesale price for Cobenfy, or more than $22,000 per year, which is in line with other brand name antipsychotics. Competition is coming from other muscarinic receptor ...

BMS has strengthened its pipeline with these acquisitions, and it now has over 50 compounds in development. BMS has recently secured the U.S. FDA approval for its schizophrenia drug – Cobenfy ...

P eople with schizophrenia now have a new drug to treat the neuropsychiatric condition. Cobenfy, which comes in capsule form, works on the muscarinic nervous system, a different network from ...

Investing.com -- Jefferies upgraded Bristol-Myers Squibb Company (NYSE:BMY) to "buy" from "hold" and raised its price target by $7 to $70, amid an improved confidence in the company’s product ...

Cobenfy ® is supplied in 50mg/20mg, 100mg/20mg, and 125mg/30mg capsule strengths of xanomeline and trospium chloride.

How Is Cobenfy Supplied and How Do I Take It? Cobenfy is an oral capsule that is taken twice daily for schizophrenia. Cobenfy is available in three strengths of capsules, each of which comes in a ...